These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

921 related articles for article (PubMed ID: 23688078)

  • 21. Updated chemical scaffolds of ABCG2 inhibitors and their structure-inhibition relationships for future development.
    Moinul M; Amin SA; Jha T; Gayen S
    Eur J Med Chem; 2022 Nov; 241():114628. PubMed ID: 35944339
    [TBL] [Abstract][Full Text] [Related]  

  • 22. 9-Deazapurines as Broad-Spectrum Inhibitors of the ABC Transport Proteins P-Glycoprotein, Multidrug Resistance-Associated Protein 1, and Breast Cancer Resistance Protein.
    Stefan K; Schmitt SM; Wiese M
    J Med Chem; 2017 Nov; 60(21):8758-8780. PubMed ID: 29016119
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Overcoming ABC transporter-mediated multidrug resistance: Molecular mechanisms and novel therapeutic drug strategies.
    Li W; Zhang H; Assaraf YG; Zhao K; Xu X; Xie J; Yang DH; Chen ZS
    Drug Resist Updat; 2016 Jul; 27():14-29. PubMed ID: 27449595
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sensitization of ABCG2-overexpressing cells to conventional chemotherapeutic agent by sunitinib was associated with inhibiting the function of ABCG2.
    Dai CL; Liang YJ; Wang YS; Tiwari AK; Yan YY; Wang F; Chen ZS; Tong XZ; Fu LW
    Cancer Lett; 2009 Jun; 279(1):74-83. PubMed ID: 19232821
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Computational classification models for predicting the interaction of drugs with P-glycoprotein and breast cancer resistance protein.
    Erić S; Kalinić M; Ilić K; Zloh M
    SAR QSAR Environ Res; 2014; 25(12):939-66. PubMed ID: 25435255
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Drug resistance mediated by ABC transporters].
    Yoshikawa M; Ito A; Ishikawa T; Ikegami Y
    Gan To Kagaku Ryoho; 2004 Jan; 31(1):1-6. PubMed ID: 14750312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human ABC transporter ABCG2 in cancer chemotherapy: drug molecular design to circumvent multidrug resistance.
    Ishikawa T; Saito H; Hirano H; Inoue Y; Ikegami Y
    Methods Mol Biol; 2012; 910():267-78. PubMed ID: 22821599
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multidrug resistance in cancer chemotherapy and xenobiotic protection mediated by the half ATP-binding cassette transporter ABCG2.
    Han B; Zhang JT
    Curr Med Chem Anticancer Agents; 2004 Jan; 4(1):31-42. PubMed ID: 14754410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Modulation of multidrug resistance efflux pump activity to overcome chemoresistance in cancer.
    Modok S; Mellor HR; Callaghan R
    Curr Opin Pharmacol; 2006 Aug; 6(4):350-4. PubMed ID: 16690355
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A template model for studying anticancer drug efflux transporter inhibitors in vitro.
    Sostelly A; Payen L; Guitton J; Di Pietro A; Falson P; Honorat M; Valdameri G; Geze A; Boumendjel A; Freyer G; Tod M
    Fundam Clin Pharmacol; 2013 Oct; 27(5):544-56. PubMed ID: 22882086
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of ceritinib (LDK378) on enhancement of chemotherapeutic agents in ABCB1 and ABCG2 overexpressing cells in vitro and in vivo.
    Hu J; Zhang X; Wang F; Wang X; Yang K; Xu M; To KK; Li Q; Fu L
    Oncotarget; 2015 Dec; 6(42):44643-59. PubMed ID: 26556876
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Arylamino Esters As P-Glycoprotein Modulators: SAR Studies to Establish Requirements for Potency and Selectivity.
    Teodori E; Dei S; Floriddia E; Perrone MG; Manetti D; Romanelli MN; Contino M; Colabufo NA
    ChemMedChem; 2015 Aug; 10(8):1339-43. PubMed ID: 26012726
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Breast cancer resistance protein (BCRP/ABCG2): its role in multidrug resistance and regulation of its gene expression.
    Nakanishi T; Ross DD
    Chin J Cancer; 2012 Feb; 31(2):73-99. PubMed ID: 22098950
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Marine natural products as breast cancer resistance protein inhibitors.
    Cherigo L; Lopez D; Martinez-Luis S
    Mar Drugs; 2015 Apr; 13(4):2010-29. PubMed ID: 25854646
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Elacridar enhances the cytotoxic effects of sunitinib and prevents multidrug resistance in renal carcinoma cells.
    Sato H; Siddig S; Uzu M; Suzuki S; Nomura Y; Kashiba T; Gushimiyagi K; Sekine Y; Uehara T; Arano Y; Yamaura K; Ueno K
    Eur J Pharmacol; 2015 Jan; 746():258-66. PubMed ID: 25455500
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Inhibitors of cancer cell multidrug resistance mediated by breast cancer resistance protein (BCRP/ABCG2).
    Ahmed-Belkacem A; Pozza A; Macalou S; Pérez-Victoria JM; Boumendjel A; Di Pietro A
    Anticancer Drugs; 2006 Mar; 17(3):239-43. PubMed ID: 16520651
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversing agents for ATP-binding cassette drug transporters.
    Lee CH
    Methods Mol Biol; 2010; 596():325-40. PubMed ID: 19949930
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multidrug resistance transporters and modulation.
    Tan B; Piwnica-Worms D; Ratner L
    Curr Opin Oncol; 2000 Sep; 12(5):450-8. PubMed ID: 10975553
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.